

Acute Leukemia FORUM 2018

Thursday April 12, 2018

Session 1: Advances in Myelodysplasia

Moderators: *Hetty Carraway, MD*
B. Douglas Smith, MD

- 1:00 Introduction
Jacob M. Rowe, MD, Co-Chairman
- 1:05-1:20 **What biologic factors predict for transformation to AML?**
Rafael Bejar, MD, PhD
- 1:20-1:30 Discussion
- 1:30-1:45 **Do molecular genetics drive therapeutic strategy in MDS?**
Stephen Nimer, MD
- 1:45-1:55 Discussion
- 1:55-2:10 **Must hypomethylating agents be given prior to transplant?**
Mikkael Sekeres, MD, MS
- 2:10-2:20 Discussion
- 2:20-2:35 **What is the optimal strategy for patients with who have failed hypomethylating therapy?**
Rami Komrokji, MD
- 2:35-2:45 Discussion
- 2:45-3:05 Break

Session 2: Novel Strategies in ALL

Moderators: *Dan Douer, MD*
Richard Larson, MD

- 3:05-3:20 **Why and how to treat Ph-like ALL?**
Kathryn G. Roberts, PhD
- 3:25-3:30 Discussion
- 3:30-3:45 **Is transplant still an imperative in Ph+ ALL?**
Mark Litzow, MD
- 3:45-3:55 Discussion
- 3:55-4:10 **Can one target T-cell ALL?**

Acute Leukemia FORUM 2018

Adolfo Ferrando, MD, PhD

- | | |
|-----------|--|
| 4:10-4:20 | Discussion |
| 4:20-4:35 | Should immunologic strategies be incorporated into newly diagnosed ALL?
<i>Wendy Stock, MD</i> |
| 4:35-4:45 | Discussion |
| 4:45-5:30 | Oral poster presenters (3)
Each 10 minutes; 5 minutes Q & A |
| 5:30-5:45 | Young Investigator Award |
| 5:45-6:30 | Poster Session/Reception |

Acute Leukemia FORUM 2018

Friday April 13, 2018

7:00–7:40 Registration and Breakfast

7:45–7:50 Introduction

Jacob M. Rowe, MD, Co-Chairman

Session 1: Basic Biology

Moderators: *Ross Levine, MD*
Marshall Lichtman, MD

7:50–8:05 **Mutational complexity in AML**
Omar Abdel-Wahab, MD

8:05–8:15 Discussion

8:15–8:30 **Genetic predisposition to AML**
Lucy Godley, MD

8:30–8:40 Discussion

8:40–8:55 **Mechanisms of resistance in TP53 mutated AML**
John S. Welch, MD, PhD

8:55–9:05 Discussion

9:05–9:25 Break

Session 2: Therapy of Induction, Post-remission and Relapse

Moderators: *Harry Erba, MD, PhD*
Selina Luger, MD

9:30–9:45 **Is there a standard of care for relapsed AML?**
Bruno Medeiros, MD

9:45–9:55 Discussion

9:55–10:10 **Is the overall survival for older adults finally improving?**
Jeffrey E. Lancet, MD

10:10–10:20 Discussion

10:20–10:35 **Which novel agents are likely to change practice?**
Daniel Pollyea, MD

10:35–10:45 Discussion

Acute Leukemia FORUM 2018

11:10–11:25 **Is it time to routinely incorporate MRD into practice?**
Farhad Ravandi, MD

11:00–11:10 Discussion

10:45–11:00 **Which FLT3 inhibitor holds the greatest promise?**
Richard M. Stone, MD

11:25–11:35 Discussion

11:35–12:35 Lunch

Session 3: Bone Marrow Transplantation

Moderators: *Armand Keating, MD*
Stephanie Lee, MD

12:40–12:55 **Who should be transplanted at diagnosis, without any pre-transplant therapy?**
Robert J. Soiffer, MD

12:55–1:05 Discussion

1:05–1:20 **When to transplant an AML patient who is MRD-positive post-consolidation?**
Frederick R. Appelbaum, MD

1:20–1:30 Discussion

1:30–1:45 **Are haploidentical transplants now the preferred alternative donor graft source?**
Daniel J. Weisdorf, MD

1:45–1:55 Discussion

1:55–2:10 **Why is a 3-year NRM following allogeneic transplantation still stuck at approximately 20%?**
John Barrett, MD

2:10–2:20 Discussion

2:20–2:40 Break

Session 4: Supportive Care and Perspective

Moderators: *Nancy Berliner, MD*
Kenneth Kaushansky, MD

2:45–3:00 **Immune reconstruction following ablative and non-myeloablative therapies**
Marcel RM van den Brink, MD, PhD

Acute Leukemia FORUM 2018

3:00–3:10 Discussion

Ernest Beutler Memorial Lecture

3:10–3:20 **Introduction**

David Porter, MD

3:20–3:50 **CAR-T Therapy. From Bench to the Bedside**

Carl June, MD

3:50–3:55 Discussion

3:55–4:00 **Concluding Remarks and Close**

Martin S. Tallman, MD, Co-Chairman